

09421971
***** STN Columbus *****

FILE 'HOME' ENTERED AT 07:43:29 ON 20 AUG 2001

=> e medline biosis embase caplus uspatfull

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
The EXPAND command is used to look at the index in a file
which has an index. This file does not have an index.

=> s chimeric (p) steroid (p) receptor (p) linker (p) dimer?

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND
command can only be used to look at the index in a file which has an
index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> file medline biosis embase caplus uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 07:44:42 ON 20 AUG 2001

FILE 'BIOSIS' ENTERED AT 07:44:42 ON 20 AUG 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 07:44:42 ON 20 AUG 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 07:44:42 ON 20 AUG 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 07:44:42 ON 20 AUG 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> s chimeric (p) steroid (p) receptor (p) linker (p) dimer?

L1 1 CHIMERIC (P) STEROID (P) RECEPTOR (P) LINKER (P) DIMER?

=> d l1 total ibib kwic

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:380609 CAPLUS
DOCUMENT NUMBER: 135:805
TITLE: Chimeric proteins containing hormone receptor
functional entities and methods of their use
INVENTOR(S): Gage, Fred H.; Suhr, Steven T.; Gil, Elad B.; Senut,
Marie-Claude C.
PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036447	A2	20010525	WO 2000-US41224	20001017

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-421971 A1 19991020

AB The invention provides **chimeric** proteins having at least two functional protein units, each contg. the **dimerization** domain of a member of the **steroid**/thyroid hormone nuclear **receptor** superfamily. The **chimeric** proteins can fold under crystn. conditions to form functional entities. The functional entities optionally contain a novel flexible peptide **linker** of variable lengths between at least two of the protein units. In a preferred embodiment, the **linker** is designed to be increased in increments of 12 amino acids each to aid in prepn. of variant **chimeric** proteins. The DNA binding characteristics of the invention functional entities differ from those of wild-type complexes formed between "monomeric" **receptors** and their binding partners. Some functional entities, e.g. **dimers** expressed as fusion proteins, transactivate responsive promoters in a manner similar to wild-type complexes, while others do not promote transactivation and function instead essentially as constitutive repressors. The invention further provides nucleotide sequences encoding the invention **chimeric** proteins, cells contg. such nucleotide sequences, and methods for using the invention **chimeric** proteins to modulate expression of one or more exogenous genes in a subject organism. In addn., isolated protein crystals suitable for x-ray diffraction anal. and methods for obtaining putative ligands for the invention **chimeric** proteins are provided.

=> s chimeric (p) steroid (p) receptor (p) linker

L2 11 CHIMERIC (P) STEROID (P) RECEPTOR (P) LINKER

=> dup rem 123

L23 IS NOT VALID HERE

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> dup rem 12

PROCESSING COMPLETED FOR L2

L3 11 DUP REM L2 (0 DUPLICATES REMOVED)

=> d l3 total ibib kwic

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:380609 CAPLUS

DOCUMENT NUMBER: 135:805

TITLE: Chimeric proteins containing hormone receptor functional entities and methods of their use

INVENTOR(S): Gage, Fred H.; Suhr, Steven T.; Gil, Elad B.; Senut, Marie-Claude C.

PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036447	A2	20010525	WO 2000-US41224	20001017
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 1999-421971 A1 19991020

AB The invention provides **chimeric** proteins having at least two functional protein units, each contg. the dimerization domain of a member of the **steroid/thyroid hormone nuclear receptor** superfamily. The **chimeric** proteins can fold under crystn. conditions to form functional entities. The functional entities optionally contain a novel flexible peptide **linker** of variable lengths between at least two of the protein units. In a preferred embodiment, the **linker** is designed to be increased in increments of 12 amino acids each to aid in prepn. of variant **chimeric** proteins. The DNA binding characteristics of the invention functional entities differ from those of wild-type complexes formed between "monomeric" **receptors** and their binding partners. Some functional entities, e.g. dimers expressed as fusion proteins, transactivate responsive promoters in a manner similar to wild-type complexes, while others do not promote transactivation and function instead essentially as constitutive repressors. The invention further provides nucleotide sequences encoding the invention **chimeric** proteins, cells contg. such nucleotide sequences, and methods for using the invention **chimeric** proteins to modulate expression of one or more exogenous genes in a subject organism. In addn., isolated protein crystals suitable for x-ray diffraction anal. and methods for obtaining putative ligands for the invention **chimeric** proteins are provided.

L3 ANSWER 2 OF 11 USPATFULL

ACCESSION NUMBER: 2000:174415 USPATFULL

TITLE: Regulated transcription of targeted genes and other biological events

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States

PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6165787		20001226
APPLICATION INFO.:	US 1998-87647		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-478386, filed on 7 Jun 1995, now patented, Pat. No. US 5830462 And a		

continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266

which

is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US

478386

which is a division of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337

which

is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Berstein, David L., Hausdorff, Sharon F., Clauss, Isabelle M.
NUMBER OF CLAIMS: 129
EXEMPLARY CLAIM: 62
NUMBER OF DRAWINGS: 36 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 5058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1) -rbm.sub.(n) are

receptor binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently

linked

("--") to two or more rbm moieties.. . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cydosporin-type moiety, a **steroid** or tetracycline.

Cydosporin-type moieties include cydosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or.

. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or

chimeric molecule containing a modified **receptor** domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of

magnitude

less than their Kd values with respect to a naturally occurring

receptor protein. **Linker** moieties are also described

in detail later, but for the sake of illustration, include such

moieties

as a C2-C20 alkylene,. . .

L3 ANSWER 3 OF 11 USPATFULL

ACCESSION NUMBER: 2000:50686 USPATFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States

PATENT ASSIGNEE(S): Board of Trustees of Leland S. Stanford Jr. Univ.,

Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054436		20000425
APPLICATION INFO.:	US 1998-87811		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Berstein, David L., Hausdorff, Sharon F., Clauss, Isabelle M.		
NUMBER OF CLAIMS:	64		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	5061		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1) -rbm.sub.(n) are **receptor** binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently linked

("") to two or more rbm moieties.. . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline. Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or **chimeric** molecule containing a modified **receptor** domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of magnitude less than their Kd values with respect to a naturally occurring **receptor** protein. **Linker** moieties are also described in detail later, but for the sake of illustration, include such moieties as a C2-C20 alkylene, . . .

L3 ANSWER 4 OF 11 USPATFULL
ACCESSION NUMBER: 2000:40892 USPATFULL
TITLE: Regulated transcription of targeted genes and other biological events
INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States

PATENT ASSIGNEE(S):

Spencer, David M., Los Altos, CA, United States
 Wandless, Thomas J., Cambridge, MA, United States
 Belshaw, Peter, Cambridge, MA, United States
 Ho, Steffan N., San Diego, CA, United States
 Board of Trustees of Leland Stanford Jr. University,
 Stanford, CA, United States (U.S. corporation)
 President and Fellows of Harvard College, Cambridge,
 MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6046047		20000404
APPLICATION INFO.:	US 1998-157230		19980916 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266		

which

is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US

388653

which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Degen, Nancy
 ASSISTANT EXAMINER: Schwartzman, Robert
 LEGAL REPRESENTATIVE: Bernstein, David L., Vincent, Matthew P., Clauss, Isabelle M.

NUMBER OF CLAIMS: 127
 EXEMPLARY CLAIM: 65
 NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
 LINE COUNT: 4582

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1) -rbm.sub.(n) are **receptor** binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently

linked

("--") to two or more rbm moieties.. . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline. Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or **chimeric** molecule containing a modified **receptor** domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of magnitude less than their Kd values with respect to a naturally occurring **receptor** protein. **Linker** moieties are also described in detail later, but for the sake of illustration, include such moieties

as a C2-C20 alkylene, . . .

L3 ANSWER 5 OF 11 USPATFULL

ACCESSION NUMBER: 2000:37639 USPATFULL

TITLE: Regulated transcription of targeted genes and other biological events

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Ho, Steffan N., San Diego, CA, United States
Belshaw, Peter, Cambridge, MA, United States

PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. Univ.,
Stanford, CA, United States (U.S. corporation)
President & Fellows of Harvard College, Cambridge, MA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6043082		20000328
APPLICATION INFO.:	US 1998-157753		19980916 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned And a continuation of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Berstein, David L., Vincent, Matthew P., Clauss, Isabelle M.		
NUMBER OF CLAIMS:	71		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 36 Drawing Page(s)		
LINE COUNT:	4828		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1)-rbm.sub.(n) are **receptor** binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently linked

("--") to two or more rbm moieties. . . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline.

Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or.

. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of

FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or

chimeric molecule containing a modified **receptor**

domain with a Kd value at least one, and preferably 2, and more

preferably 3 and even more preferably 4 or 5 or more orders of magnitude

less than their Kd values with respect to a naturally occurring **receptor** protein. **Linker** moieties are also described in detail later, but for the sake of illustration, include such moieties as a C2-C20 alkylene, . . .

L3 ANSWER 6 OF 11 USPATFULL

ACCESSION NUMBER: 2000:1861 USPATFULL

TITLE: Regulated transcription of targeted genes and other biological events

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States

PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6011018		20000104
APPLICATION INFO.:	US 1998-87716		19980529 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-388653, filed on 14 Feb 1995, now patented, Pat. No. US 5869337 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266		

which

is a continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Berstein, David L., Hausdorff, Sharon F., Vincent, Matthew P.

NUMBER OF CLAIMS: 70
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 36 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4687

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1)-- rbm.sub.(n) are

receptor binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently linked

("") to two or more rbm moieties. . . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline. Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or.

. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or **chimeric** molecule containing a modified **receptor** domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of magnitude less than their Kd values with respect to a naturally occurring **receptor** protein. **Linker** moieties are also described in detail later, but for the sake of illustration, include such moieties as a C2-C20 alkylene, . . .

L3 ANSWER 7 OF 11 USPATFULL

ACCESSION NUMBER: 1999:155696 USPATFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
Board of Trustees of the Leland S. Stanford, Jr.

PATENT ASSIGNEE(S): Univ.,
Stanford, CA, United States (U.S. corporation)
President and Fellows of Harvard College, Cambridge,
MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994313		19991130
APPLICATION INFO.:	US 1995-483898		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-292597, filed on 18 Aug 1994, now patented, Pat. No. US 5834266 which is a continuation-in-part of Ser. No. US 1994-196043, filed on 14 Feb 1994, now abandoned And Ser. No. US 1994-179143, filed on 17 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993, now abandoned, said Ser. No. US 196043 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Berstein, David L., Hausdorff, Sharon F., Vincent, Matthew P.		
NUMBER OF CLAIMS:	48		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	32 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	4791		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1) -rbm.sub.(n) are **receptor** binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently linked

("--") to two or more rbm moieties.. . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a

cyclosporin-type moiety, a **steroid** or tetracycline.
 Cyclosporin-type moieties include cyclosporin and derivatives thereof
 which are capable of binding to a cyclophilin, naturally occurring or.
 . . . Kd value below about 10×10^{-6} M. In some embodiments it is
 preferred that the ligand bind to a naturally occurring **receptor**
 with a Kd value greater than about 10×10^{-6} M and more preferably
 greater than about 10×10^{-5} M. Illustrative ligands of. . . of
 FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or
 both, which ligands bind to a modified **receptor** or
chimeric molecule containing a modified **receptor**
 domain with a Kd value at least one, and preferably 2, and more
 preferably 3 and even more preferably 4 or 5 or more orders of
 magnitude
 less than their Kd values with respect to a naturally occurring
receptor protein. **Linker** moieties are also described
 in detail later, but for the sake of illustration, include such
 moieties
 as a C2-C20 alkylene, . . .

L3 ANSWER 8 OF 11 USPATFULL

ACCESSION NUMBER: 1999:19001 USPATFULL

TITLE: Regulated transcription of targeted genes and other
 biological events

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
 Schreiber, Stuart L., Cambridge, MA, United States
 Spencer, David M., Los Altos, CA, United States
 Wandless, Thomas J., Cambridge, MA, United States
 Belshaw, Peter, Cambridge, MA, United States
 PATENT ASSIGNEE(S): President and Fellows of Harvard College, Cambridge,
 MA, United States (U.S. corporation)
 Board of Trustees of Leland S. Stanford Jr.

University,

Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5869337		19990209
APPLICATION INFO.:	US 1995-388653		19950214 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994 And Ser. No. US 1994-292597, filed on		

18

Aug 1994, now patented, Pat. No. US 5834266, each

Ser.

No. US which is a continuation-in-part of Ser. No. US
 1994-179748, filed on 7 Jan 1994, now abandoned which
 is a continuation-in-part of Ser. No. US 1993-92977,
 filed on 16 Jul 1993, now abandoned which is a
 continuation-in-part of Ser. No. US 1993-17931, filed
 on 12 Feb 1993, now abandoned, said Ser. No. US

292597

which is a continuation-in-part of Ser. No. US
 1994-179148, filed on 7 Jan 1994, now abandoned which
 is a continuation-in-part of Ser. No. US 1993-93499,
 filed on 16 Jul 1993, now abandoned which is a
 continuation-in-part of Ser. No. US 17931

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Elliott, George C.

ASSISTANT EXAMINER:

Schwartzman, Robert

LEGAL REPRESENTATIVE:

Vincent, Matthew P., Clauss, Isabelle M. Foley, Hoag &
 Eliot LLP

NUMBER OF CLAIMS:

165

EXEMPLARY CLAIM:

85

NUMBER OF DRAWINGS:

37 Drawing Figure(s); 36 Drawing Page(s)

LINE COUNT:

4716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm.sub.(1) -rbm.sub.(n) are **receptor** binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently linked ("--") to two or more rbm moieties.. . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline. Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or **chimeric** molecule containing a modified **receptor** domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of magnitude less than their Kd values with respect to a naturally occurring **receptor** protein. **Linker** moieties are also described in detail later, but for the sake of illustration, include such moieties as a C2-C20 alkylene,. . .

L3 ANSWER 9 OF 11 USPATFULL

ACCESSION NUMBER: 1998:138709 USPATFULL

TITLE: Regulated apoptosis

INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Somerville, MA, United States
PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
Board of Trustees of Leland Stanford Jr. University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 5834266		19981110
APPLICATION INFO.:	US 1994-292597		19940818 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-179143, filed on 7 Jan 1994, now abandoned And Ser. No. US 1994-179748, filed on 7 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned , said Ser. No. US 179143		
	which is a continuation-in-part of Ser. No. US 1993-93499, filed on 16 Jul 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Vincent, Matthew P., Clauss, Isabelle M.Foley, Hoag & Eliot LLP		
NUMBER OF CLAIMS:	235		
EXEMPLARY CLAIM:	118		
NUMBER OF DRAWINGS:	35 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	5299		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
SUMM	wherein n is an integer from 2 to about 5, rbm.sub.(1) --rbm.sub.(n) are		

receptor binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently linked ("--") to two or more rbm moieties. . . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline. Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or. . . . Kd value below about 10×10^{-6} M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10×10^{-6} M and more preferably greater than about 10×10^{-5} M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or **chimeric** molecule containing a modified **receptor** domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of magnitude less than their Kd values with respect to a naturally occurring **receptor** protein. **Linker** moieties are also described in detail later, but for the sake of illustration, include such moieties as a C2-C20 alkylene, . . .

L3 ANSWER 10 OF 11 USPATFULL

ACCESSION NUMBER: 1998:134626 USPATFULL
 TITLE: Regulated transcription of targeted genes and other biological events
 INVENTOR(S): Crabtree, Gerald R., Woodside, CA, United States
 Schreiber, Stuart L., Cambridge, MA, United States
 Spencer, David M., Los Altos, CA, United States
 Wandless, Thomas J., Cambridge, MA, United States
 Belshaw, Peter, Cambridge, MA, United States
 PATENT ASSIGNEE(S): President & Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
 Board of Trustees of Leland S. Stanford, Jr. University, Stanford, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830462		19981103
APPLICATION INFO.:	US 1995-478386		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-388653, filed on 14 Feb 1995 And a continuation-in-part of Ser. No. US 1994-292597, filed on 18 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-179748, filed on 7 Jan 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-92977, filed on 16 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-17931, filed on 12 Feb 1993, now abandoned , said Ser. No. US		

388653

which is a continuation-in-part of Ser. No. US 1994-196043, filed on 11 Feb 1994 which is a continuation-in-part of Ser. No. US 179748 which is a continuation-in-part of Ser. No. US 92977 which is a continuation-in-part of Ser. No. US 17931

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Elliott, George C.
 ASSISTANT EXAMINER: Schwartzman, Robert
 LEGAL REPRESENTATIVE: Vincent, Matthew P., Clauss, Isabelle M.Foley, Hoag & Eliot LLP

NUMBER OF CLAIMS: 127
EXEMPLARY CLAIM: 34
NUMBER OF DRAWINGS: 37 Drawing Figure(s); 36 Drawing Page(s)
LINE COUNT: 4581

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM wherein n is an integer from 2 to about 5, rbm(.sub.1)-rbm.sub.(n) are

receptor binding moieties which may be the same or different and which are capable of binding to the **chimeric** protein(s). The rbm moieties are covalently attached to a **linker** moiety which is a bi- or multi-functional molecule capable of being covalently

linked

("--") to two or more rbm moieties. . . . those in which the rbm moieties are the same or different and comprise an FK506-type moiety, a cyclosporin-type moiety, a **steroid** or tetracycline.

Cyclosporin-type moieties include cyclosporin and derivatives thereof which are capable of binding to a cyclophilin, naturally occurring or.

. . . Kd value below about 10.sup.-6 M. In some embodiments it is preferred that the ligand bind to a naturally occurring **receptor** with a Kd value greater than about 10.sup.-6 M and more preferably greater than about 10.sup.-5 M. Illustrative ligands of. . . of FK506, FK520, rapamycin or a derivative thereof modified at C9, C10 or both, which ligands bind to a modified **receptor** or

chimeric molecule containing a modified **receptor**

domain with a Kd value at least one, and preferably 2, and more preferably 3 and even more preferably 4 or 5 or more orders of

magnitude

less than their Kd values with respect to a naturally occurring

receptor protein. **Linker** moieties are also described

in detail later, but for the sake of illustration, include such

moieties

as a C2-C20 alkylene, . . .

L3 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:476304 CAPLUS

DOCUMENT NUMBER: 127:105220

TITLE: Monitoring DNA binding molecules in living cells containing a steroid receptor response element array using a fluorescent chimeric protein of the steroid receptor

INVENTOR(S): Htun, Han; Hager, Gordon L.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA;

Htun, Han; Hager, Gordon L.

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9720931	A1	19970612	WO 1996-US19516	19961206
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2239951	AA	19970612	CA 1996-2239951	19961206
AU 9712834	A1	19970627	AU 1997-12834	19961206
PRIORITY APPLN. INFO.:			US 1995-8373 P	19951208
			WO 1996-US19516 W	19961206
AB	A method of screening for a compd. that binds to a selected nucleic acid			

is provided that comprises contacting a compd. fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compd. The location of fluorescence within the cell is detected such that fluorescence aggregated at the site of the nucleic acid array indicates a compd. that binds to the selected nucleic acid. In particular compds. such a transcription factor can be screened. Reagents for such method are provided including a mammalian cell having a plurality of **steroid receptor** response elements in an array such that the response element can be directly detected when bound by fluorescently labeled **steroid receptor** and a **chimeric** protein comprising a fluorescent protein fused to a **steroid receptor**. Thus, a **chimeric** protein is constructed comprising a 27-kDa green fluorescent protein (GFP, from *Aequorea victoria*) and fused by a (Gly-Ala)₅ peptide **linker** to the N-terminal second residue of rat glucocorticoid **receptor** (GR). Improved fluorescence is achieved by using a GFP variant contg. a serine-65 to threonine substitution, which increases the efficiency of formation of the GFP chromophore, and a GR variant contg. a cysteine-656 to glycine mutation has higher affinity for its ligand than endogenous **receptor**. A mammalian cell line named 3134 was derived by transfection of murine mammary carcinoma line C127 with a plasmid contg. 3 functional segments: (a) the bovine papilloma virus 69% transforming fragment serving as a replicon in mammalian cells; (b) mouse mammary tumor virus (MMTV) LTR is a **steroid** responsive promoter and contains the GR binding sites; and (c) the Ha-v-ras gene is a transforming oncogene and serves as a reporter for the MMTV promoter. The MMTV LTRs are organized in a head-to-tail tandem array of .apprx.200 copies, and since each promoter sequence contains 4 GR binding sites, the complete array contains 100 GR binding sites. This cell is used to visualize directly the interaction between the fluorescent, **chimeric** GR and its binding site in chromatin in living cells. The system allows screening for DNA-binding ligands that (1) activate gene targeting by **steroid receptor**, (2) activate translocation of the **steroid receptor** to the nucleus, (3) are antagonists or agonists of the **steroid receptor**.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.34	31.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.76	-1.76

STN INTERNATIONAL LOGOFF AT 07:46:44 ON 20 AUG 2001